Update in Diagnosis and Management of Severe Cutaneous Adverse Reactions: Emerging Therapies and Evolving Presentations
Canadian Dermatology Today · 2025
DOI: 10.58931/cdt.2025.62142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Dermatology Today, 2025. Verfasst von Jennifer Lipson. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Severe cutaneous adverse drug reactions (SCARs) represent some of the most critical and potentially life-threatening conditions encountered in dermatology. These reactions include Stevens‑Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)—also referred to as Drug-Induced Hypersensitivity Syndrome (DIHS), Acute Generalized Exanthematous Pustulosis (AGEP), and Generalized Bullous Fixed Drug Eruption (GBFDE). All of these are classified as T-cell mediated hypersensitivity reactions. The development of SCARs is influenced by a complex interplay of genetic predisposition, variations in drug metabolism, and, in some cases, concurrent infections. In this update, I will review the latest advances in the diagnosis and management of SCARs, highlighting emerging patterns of presentation, differential diagnoses, and therapeutic strategies that are impacting clinical practice.
Zitieren
APA
Lipson, J. (2025). Update in Diagnosis and Management of Severe Cutaneous Adverse Reactions: Emerging Therapies and Evolving Presentations. Canadian Dermatology Today. https://doi.org/10.58931/cdt.2025.62142
Vancouver
Lipson J. Update in Diagnosis and Management of Severe Cutaneous Adverse Reactions: Emerging Therapies and Evolving Presentations. Canadian Dermatology Today. 2025. doi:10.58931/cdt.2025.62142
BibTeX
@article{Lipson2025,
author = {Lipson, Jennifer},
title = {Update in Diagnosis and Management of Severe Cutaneous Adverse Reactions: Emerging Therapies and Evolving Presentations},
journal = {Canadian Dermatology Today},
year = {2025},
doi = {10.58931/cdt.2025.62142}
}
EUVIMED